Compare LTC Properties Inc (LTC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Recursion Pharmaceuticals Inc — how do they compare? LTC Properties Inc trades at $42.53 (market cap $2.27B), while Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B). The key difference: LTC Properties Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and LTC Properties Inc pays a 5.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LTC | RXRX | |
|---|---|---|
Market Cap | $2.27B | $2.14B |
Volume | 574,171 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $6.79 |
52-Week Low | $33.98 | $2.84 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $3.01B | $1.66B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.46, up 1.55% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 61.72% gross margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, though cash flow trends show significant investing outflows. Analyst consensus targets $49.67 with 32% buy ratings amid balanced risk-reward outlook.
LTC presents a balanced opportunity with steady income from monthly dividends and demographic tailwinds in senior housing, offset by execution risks from rapid portfolio transformation and rising interest rate sensitivity. The stock trades at reasonable valuations (P/E 15.02) but faces headwinds from its SHOP transition strategy and macroeconomic pressures on REIT valuations.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
